289 related articles for article (PubMed ID: 25036792)
1. Selenadiazole derivatives as potent thioredoxin reductase inhibitors that enhance the radiosensitivity of cancer cells.
Liang YW; Zheng J; Li X; Zheng W; Chen T
Eur J Med Chem; 2014 Sep; 84():335-42. PubMed ID: 25036792
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of cancer cells to radiation by selenadiazole derivatives by regulation of ROS-mediated DNA damage and ERK and AKT pathways.
Xie Q; Zhou Y; Lan G; Yang L; Zheng W; Liang Y; Chen T
Biochem Biophys Res Commun; 2014 Jun; 449(1):88-93. PubMed ID: 24813998
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy.
He J; Li D; Xiong K; Ge Y; Jin H; Zhang G; Hong M; Tian Y; Yin J; Zeng H
Bioorg Med Chem; 2012 Jun; 20(12):3816-27. PubMed ID: 22579620
[TBL] [Abstract][Full Text] [Related]
4. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M
Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723
[TBL] [Abstract][Full Text] [Related]
5. Microwave-Assisted Syntheses of Benzimidazole-Containing Selenadiazole Derivatives That Induce Cell-Cycle Arrest and Apoptosis in Human Breast Cancer Cells by Activation of the ROS/AKT Pathway.
Liang Y; Zhou Y; Deng S; Chen T
ChemMedChem; 2016 Oct; 11(20):2339-2346. PubMed ID: 27677422
[TBL] [Abstract][Full Text] [Related]
6. Auranofin, an inhibitor of thioredoxin reductase, induces apoptosis in hepatocellular carcinoma Hep3B cells by generation of reactive oxygen species.
Hwang-Bo H; Jeong JW; Han MH; Park C; Hong SH; Kim GY; Moon SK; Cheong J; Kim WJ; Yoo YH; Choi YH
Gen Physiol Biophys; 2017 Apr; 36(2):117-128. PubMed ID: 28218611
[TBL] [Abstract][Full Text] [Related]
7. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
[TBL] [Abstract][Full Text] [Related]
8. Novel Phenylmethylenecyclohexenone Derivatives as Potent TrxR Inhibitors Display High Antiproliferative Activity and Induce ROS, Apoptosis, and DNA Damage.
Wang X; Qian J; Zhu P; Hua R; Liu J; Hang J; Meng C; Shan W; Miao J; Ling Y
ChemMedChem; 2021 Feb; 16(4):702-712. PubMed ID: 33085980
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of xanthohumol analogues and discovery of potent thioredoxin reductase inhibitor as potential anticancer agent.
Zhang B; Duan D; Ge C; Yao J; Liu Y; Li X; Fang J
J Med Chem; 2015 Feb; 58(4):1795-805. PubMed ID: 25629304
[TBL] [Abstract][Full Text] [Related]
11. Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase.
Jayakumar S; Patwardhan RS; Pal D; Sharma D; Sandur SK
Biochem Biophys Res Commun; 2016 Sep; 478(1):446-454. PubMed ID: 27381867
[TBL] [Abstract][Full Text] [Related]
12. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of benzylidenecyclohexenones as TrxR inhibitors displaying high anticancer activity and inducing ROS, apoptosis, and autophagy.
Qian J; Xu Z; Meng C; Liu J; Hsu PL; Li Y; Zhu W; Yang Y; Morris-Natschke SL; Lee KH; Zhang Y; Ling Y
Eur J Med Chem; 2020 Oct; 204():112610. PubMed ID: 32736231
[TBL] [Abstract][Full Text] [Related]
14. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Thioredoxin System for Cancer Therapy.
Zhang J; Li X; Han X; Liu R; Fang J
Trends Pharmacol Sci; 2017 Sep; 38(9):794-808. PubMed ID: 28648527
[TBL] [Abstract][Full Text] [Related]
16. Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors.
Cheng Y; Qi Y
Anticancer Agents Med Chem; 2017; 17(8):1046-1069. PubMed ID: 28270080
[TBL] [Abstract][Full Text] [Related]
17. EM23, a natural sesquiterpene lactone, targets thioredoxin reductase to activate JNK and cell death pathways in human cervical cancer cells.
Shao FY; Wang S; Li HY; Chen WB; Wang GC; Ma DL; Wong NS; Xiao H; Liu QY; Zhou GX; Li YL; Li MM; Wang YF; Liu Z
Oncotarget; 2016 Feb; 7(6):6790-808. PubMed ID: 26758418
[TBL] [Abstract][Full Text] [Related]
18. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase.
Zhang J; Yao J; Peng S; Li X; Fang J
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):129-138. PubMed ID: 27777067
[TBL] [Abstract][Full Text] [Related]
19. Ebselen: a thioredoxin reductase-dependent catalyst for alpha-tocopherol quinone reduction.
Fang J; Zhong L; Zhao R; Holmgren A
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):103-9. PubMed ID: 15979675
[TBL] [Abstract][Full Text] [Related]
20. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
Lu J; Chew EH; Holmgren A
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12288-93. PubMed ID: 17640917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
